JP2008516970A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008516970A5 JP2008516970A5 JP2007536935A JP2007536935A JP2008516970A5 JP 2008516970 A5 JP2008516970 A5 JP 2008516970A5 JP 2007536935 A JP2007536935 A JP 2007536935A JP 2007536935 A JP2007536935 A JP 2007536935A JP 2008516970 A5 JP2008516970 A5 JP 2008516970A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- region
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61901804P | 2004-10-15 | 2004-10-15 | |
| US60/619,018 | 2004-10-15 | ||
| US64535505P | 2005-01-19 | 2005-01-19 | |
| US60/645,355 | 2005-01-19 | ||
| PCT/US2005/036994 WO2006044643A2 (en) | 2004-10-15 | 2005-10-14 | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012162676A Division JP2012197321A (ja) | 2004-10-15 | 2012-07-23 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008516970A JP2008516970A (ja) | 2008-05-22 |
| JP2008516970A5 true JP2008516970A5 (enExample) | 2008-11-06 |
| JP5222559B2 JP5222559B2 (ja) | 2013-06-26 |
Family
ID=36203547
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007536935A Expired - Fee Related JP5222559B2 (ja) | 2004-10-15 | 2005-10-14 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
| JP2012162676A Withdrawn JP2012197321A (ja) | 2004-10-15 | 2012-07-23 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012162676A Withdrawn JP2012197321A (ja) | 2004-10-15 | 2012-07-23 | 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US7491390B2 (enExample) |
| EP (1) | EP1799262A4 (enExample) |
| JP (2) | JP5222559B2 (enExample) |
| AU (1) | AU2005295595C1 (enExample) |
| CA (1) | CA2583208C (enExample) |
| WO (1) | WO2006044643A2 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58103228A (ja) * | 1981-12-16 | 1983-06-20 | Kaga Tsushin Kogyo Kk | 光スイツチ方法 |
| US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| US7641903B2 (en) * | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| WO2006044643A2 (en) * | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) * | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| CN101203241B (zh) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | 人源化抗-cd70结合物和其应用 |
| WO2007008603A1 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
| KR20080056167A (ko) * | 2005-09-26 | 2008-06-20 | 메다렉스, 인코포레이티드 | 씨디70에 대한 인간 모노크로날 항체 |
| DK2099823T4 (da) * | 2006-12-01 | 2022-05-09 | Seagen Inc | Målbindingsmiddelvarianter og anvendelser deraf |
| JP2010513306A (ja) * | 2006-12-14 | 2010-04-30 | メダレックス インコーポレーティッド | Ｃｄ７０に結合するヒト抗体およびその使用 |
| ES2402334T3 (es) | 2007-08-02 | 2013-04-30 | Gilead Biologics, Inc | Procedimientos y composiciones para el tratamiento y el diagnóstico de la fibrosis |
| KR101674097B1 (ko) * | 2008-04-11 | 2016-11-08 | 시애틀 지네틱스, 인크. | 췌장, 난소 및 다른 암의 검출 및 치료 |
| ES2458541T5 (en) | 2008-05-02 | 2025-08-04 | Seagen Inc | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| US9107935B2 (en) | 2009-01-06 | 2015-08-18 | Gilead Biologics, Inc. | Chemotherapeutic methods and compositions |
| SG178845A1 (en) | 2009-08-21 | 2012-04-27 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
| WO2011075185A1 (en) | 2009-12-18 | 2011-06-23 | Oligasis | Targeted drug phosphorylcholine polymer conjugates |
| CA2712747A1 (en) * | 2010-08-11 | 2012-02-11 | Universite De Montreal | Combinatory cancer treatment |
| CN103313727B (zh) * | 2010-09-29 | 2015-07-22 | 弗·哈夫曼-拉罗切有限公司 | 抗体组合物及使用方法 |
| KR101847523B1 (ko) | 2011-01-24 | 2018-05-28 | 연세대학교 산학협력단 | 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 |
| EP2686347B1 (en) | 2011-03-16 | 2018-05-02 | argenx BVBA | Antibodies to cd70 |
| SG11201400916XA (en) | 2011-08-22 | 2014-06-27 | Cangene Corp | Clostridium difficile antibodies |
| CN104136461B (zh) * | 2011-09-22 | 2021-06-08 | 安姆根有限公司 | Cd27l抗原结合蛋白 |
| EP3559049B1 (en) | 2011-10-28 | 2025-06-11 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| EP2785736A4 (en) | 2011-11-30 | 2015-12-09 | Wellstat Diagnostics Llc | ASSAYS, ANTIBODIES, IMMUNOGENS AND COMPOSITIONS IN CONNECTION WITH 5-FU |
| KR101645905B1 (ko) | 2012-10-12 | 2016-08-04 | 스피로즌 살 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
| US9353150B2 (en) | 2012-12-04 | 2016-05-31 | Massachusetts Institute Of Technology | Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment |
| EP2968585B1 (en) | 2013-03-13 | 2018-07-18 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| FI3677591T3 (fi) | 2013-04-29 | 2023-04-03 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| WO2015032906A2 (en) | 2013-09-05 | 2015-03-12 | Bionovion Holding B.V. | Cd70-binding peptides and method, process and use relating thereto |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| JP2017525370A (ja) | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびｔｎｆ様リガンドムテインを調製および使用する方法 |
| US10391168B1 (en) | 2014-08-22 | 2019-08-27 | University Of Bern | Anti-CD70 combination therapy |
| WO2016037644A1 (en) | 2014-09-10 | 2016-03-17 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| WO2017197045A1 (en) | 2016-05-11 | 2017-11-16 | Movassaghi Mohammad | Convergent and enantioselective total synthesis of communesin analogs |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｃｄ４７併用療法 |
| JP2019534882A (ja) | 2016-10-11 | 2019-12-05 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | 免疫介在性療法薬を有する抗体−薬物コンジュゲート |
| KR102697394B1 (ko) | 2017-02-28 | 2024-08-20 | 씨젠 인크. | 컨쥬게이션을 위한 시스테인 변이된 항체 |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| IL270415B2 (en) | 2017-05-12 | 2024-08-01 | Crispr Therapeutics Ag | Materials and methods for cell engineering and their uses in immuno-oncology |
| GB2567613A (en) | 2017-06-16 | 2019-04-24 | Argenx Bvba | Treatment for acute myeloid leukaemia |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| GB201800649D0 (en) | 2018-01-16 | 2018-02-28 | Argenx Bvba | CD70 Combination Therapy |
| IL276396B2 (en) | 2018-02-01 | 2026-01-01 | Pfizer | Chimeric antigen receptors against CD70 |
| PE20210708A1 (es) * | 2018-02-01 | 2021-04-16 | Pfizer | Anticuerpos especificos para cd70 y sus usos |
| WO2019215500A1 (en) | 2018-05-11 | 2019-11-14 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| JP2021524449A (ja) | 2018-05-23 | 2021-09-13 | アーデーセー セラピューティクス ソシエテ アノニム | 分子アジュバント |
| WO2020070288A1 (en) | 2018-10-05 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and systems for controlling the agonistic properties of antibody variable domains by light |
| TWI848030B (zh) | 2018-12-18 | 2024-07-11 | 比利時商阿根思公司 | Ｃｄ７０組合治療 |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| TWI877278B (zh) | 2019-12-30 | 2025-03-21 | 美商思進公司 | 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法 |
| WO2022002019A1 (zh) | 2020-06-30 | 2022-01-06 | 江苏恒瑞医药股份有限公司 | 抗cd70抗体及其应用 |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| CA3201499A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| WO2022078524A2 (en) | 2021-11-03 | 2022-04-21 | Hangzhou Dac Biotech Co., Ltd. | Specific conjugation of an antibody |
| EP4507779A1 (en) | 2022-04-14 | 2025-02-19 | Institut National de la Santé et de la Recherche Médicale | Methods for controlling the tumor cell killing by light |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5573924A (en) | 1992-09-08 | 1996-11-12 | Immunex Corporation | CD27 ligand |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ES2223705T3 (es) | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
| US7442776B2 (en) | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| JP2004509612A (ja) | 2000-06-05 | 2004-04-02 | アバロン ファーマシューティカルズ | ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング |
| IL157706A0 (en) * | 2001-03-02 | 2004-03-28 | Medimmune Inc | METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS |
| US7256257B2 (en) | 2001-04-30 | 2007-08-14 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| NZ533240A (en) | 2001-11-27 | 2007-12-21 | Oxford Glycosciences Uk Ltd | Use of polypeptide for the treatment of epithelial-derived cancer |
| US7261892B2 (en) | 2001-11-27 | 2007-08-28 | Celltech R&D Limited | Methods for diagnosis and treatment of epithelial-derived cancers |
| DE10231126A1 (de) | 2002-07-10 | 2004-02-05 | Daimlerchrysler Ag | Verfahren zum Starten eines Gaserzeugungssystems |
| DK1545613T3 (da) | 2002-07-31 | 2011-11-14 | Seattle Genetics Inc | Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom |
| ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
| US20080025989A1 (en) | 2003-02-20 | 2008-01-31 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| WO2004104045A1 (en) | 2003-05-23 | 2004-12-02 | Stichting Sanquin Bloedvoorziening | Therapeutical use of anti-cd70 antibody for treating or preventing aids |
| US20050282168A1 (en) * | 2003-09-29 | 2005-12-22 | Wyeth | Cell surface molecules as markers and therapeutic agents against kidney cancers |
| CN107213469A (zh) * | 2003-11-06 | 2017-09-29 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005077462A2 (en) | 2004-02-09 | 2005-08-25 | The Cbr Institute For Biomedical Research, Inc. | Cd70 inhibition for the treatment and prevention of inflammatory bowel disease |
| CN101010179A (zh) | 2004-08-05 | 2007-08-01 | 富士胶片株式会社 | 用于制造涂料的设备 |
| US7337958B2 (en) * | 2004-10-04 | 2008-03-04 | Hewlett-Packard Development Company, L.P. | Calculator device having a USB connection |
| US7641903B2 (en) * | 2004-10-15 | 2010-01-05 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| US8337838B2 (en) | 2004-10-15 | 2012-12-25 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| WO2006044643A2 (en) | 2004-10-15 | 2006-04-27 | Seattle Genetics, Inc. | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders |
| CN101203241B (zh) | 2005-04-19 | 2012-02-22 | 西雅图基因公司 | 人源化抗-cd70结合物和其应用 |
| KR20080056167A (ko) | 2005-09-26 | 2008-06-20 | 메다렉스, 인코포레이티드 | 씨디70에 대한 인간 모노크로날 항체 |
| JP2010513306A (ja) | 2006-12-14 | 2010-04-30 | メダレックス インコーポレーティッド | Ｃｄ７０に結合するヒト抗体およびその使用 |
-
2005
- 2005-10-14 WO PCT/US2005/036994 patent/WO2006044643A2/en not_active Ceased
- 2005-10-14 JP JP2007536935A patent/JP5222559B2/ja not_active Expired - Fee Related
- 2005-10-14 CA CA2583208A patent/CA2583208C/en not_active Expired - Lifetime
- 2005-10-14 EP EP05814787A patent/EP1799262A4/en not_active Withdrawn
- 2005-10-14 US US11/251,173 patent/US7491390B2/en not_active Expired - Lifetime
- 2005-10-14 AU AU2005295595A patent/AU2005295595C1/en not_active Ceased
-
2008
- 2008-01-18 US US12/016,848 patent/US20080138343A1/en not_active Abandoned
- 2008-01-18 US US12/016,814 patent/US8647624B2/en not_active Expired - Fee Related
- 2008-11-05 US US12/265,451 patent/US9051372B2/en active Active
-
2012
- 2012-07-23 JP JP2012162676A patent/JP2012197321A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008516970A5 (enExample) | ||
| RU2474588C2 (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| JP2011520898A5 (enExample) | ||
| JP2018503380A5 (enExample) | ||
| JP2020513791A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2016505556A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2009506791A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2020527144A5 (enExample) | ||
| JP2017526370A5 (enExample) | ||
| JP2019512464A5 (enExample) | ||
| JP2012501670A5 (enExample) | ||
| JP2019509055A5 (enExample) | ||
| JP2012524071A5 (enExample) | ||
| JP2010533498A5 (enExample) | ||
| JP2019525728A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| WO2006003407A3 (en) | Chimeric and humanised monoclonal antibodies against inteleukin- 13 | |
| JP2012500020A5 (enExample) | ||
| JP2020520231A5 (enExample) | ||
| JP2010532764A5 (enExample) |